Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
GI Innovation Announces Clinical Trial Collaboration for GI-102 with KEYTRUDA
GI Innovation and MSD collaborate on a Phase 2 trial combining GI-102 and KEYTRUDA for resistant liver cancer, melanoma, and renal cell carcinoma.
GI Innovation and MSD partner for trial of GI-102 and Keytruda regimen for cancer
GI Innovation and Merck & Co (MSD) collaborate on a Phase II trial to assess GI-102 combined with Keytruda for metastatic liver cancer, melanoma, and renal cell carcinoma. The trial, conducted in South Korea and the US, aims to provide treatment options for patients resistant to immuno-oncology treatments.
© Copyright 2024. All Rights Reserved by MedPath